Search

Your search keyword '"Crohn's ' showing total 950 results
Start Over Author "Crohn's Publication Year Range Last 10 years
950 results on '"Crohn's '

1. Wild Blueberries in Colitis (BlueVantage)

Author

Universität Duisburg-Essen, German Crohn's and Colitis Association (DCCV e.V.), Wilhelm Doerenkamp Foundation, and Jost Langhorst, Univ. Prof. Dr. med

Published
2024

2. Impact of Education on School Nurses’ Knowledge of Inflammatory Bowel Disease

Author

Eun Soo Kim, Ki Tae Kwon, Sung Kook Kim, Miyoung Kim, Hyun Seok Lee, Byung Ik Jang, Kyeong Ok Kim, Eun Young Kim, Yoo Jin Lee, Suk Jin Hong, Chang Heon Yang, Ben Kang, Byung-Ho Choe, and Crohn’s and Colitis Association in Daegu-Gyeongbuk

Subjects
inflammatory bowel disease, crohn disease, colitis, ulcerative, schools, nursing, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background/Aims School nurses’ knowledge of inflammatory bowel disease (IBD) has not been evaluated. We aimed to investigate school nurses’ knowledge of IBD and determine whether education could improve this knowledge. Methods : School nurses were invited to complete self-reported questionnaires on IBD. Then, IBD specialists from tertiary referral hospitals provided a 60-minute lecture with educational brochures on two occasions, with a 3-month interval. Within 6 months after the educational interventions, school nurses were asked to complete the same IBD questionnaire via e-mail. Results : Among 101 school nurses who were invited to participate, 54 nurses (53.5%) who completed two consecutive questionnaires were included in this study (median age, 45 years; range, 25 to 59 years; 100% female); 11.1% and 7.4% of the study participants had no knowledge regarding ulcerative colitis and Crohn’s disease, respectively. They had heard of IBD most frequently from doctors (33.3%), followed by internet sources (25.9%). After 6 months, the number of nurses who could explain IBD to students with over 30% confidence increased from 24 (44.5%) to 42 (77.8%) (p

Published
2019
Full Text
View/download PDF

27. Proof of Concept Human Study: Dietary Intervention to Modify Intestinal Inflammation in IBD

Author

University Medical Centre Schleswig-Holstein, Lithuanian University of Health Sciences, University Medical Center Groningen, Netherland, Weizmann Institute of Science, Israel, Sacred Heart Catholic University, Italy, Eurice European Research and project office GMBH, Germany, Orebro University, Sweden, Region Hovedstaden, Denmark, European Federation of Crohn´s and Ulcerative Colitis Associations, Belgium, and Samuel Huber, Director of the I. Department of Medicine, Prof. Dr. med.

Published
2023

31. NORDTREAT Prospective Study on Inflammatory Bowel Disease

Author

Nordic Bioscience A/S, University Hospital Bispebjerg and Frederiksberg, Aalborg University, Colitis-Crohn Foreningen, Uppsala University, Örebro University, Sweden, Lovisenberg Diakonale Hospital, University of Oslo, University of Kiel, and University Hospital of Southern Denmark

Published
2022

36. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Author

Mahadevan, Uma, Long, Millie D, Kane, Sunanda V, Roy, Abhik, Dubinsky, Marla C, Sands, Bruce E, Cohen, Russell D, Chambers, Christina D, Sandborn, William J, and Alliance, Crohn’s Colitis Foundation Clinical Research

Subjects
Preterm, Low Birth Weight and Health of the Newborn, Clinical Research, Infant Mortality, Contraception/Reproduction, Digestive Diseases, Pediatric, Inflammatory Bowel Disease, Prevention, Perinatal Period - Conditions Originating in Perinatal Period, Conditions Affecting the Embryonic and Fetal Periods, Reproductive health and childbirth, Good Health and Well Being, Adult, Anti-Inflammatory Agents, Azathioprine, Biological Products, Colitis, Ulcerative, Crohn Disease, Drug Therapy, Combination, Female, Humans, Infant, Newborn, Intestinal Mucosa, Mercaptopurine, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Prenatal Exposure Delayed Effects, Prospective Studies, United States, Crohn's Disease, Ulcerative Colitis, Crohn’s Colitis Foundation Clinical Research Alliance, Crohn’s Disease, Clinical Sciences, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology
Abstract

Background & aimsPregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child.MethodsBetween 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest.ResultsAmong 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51-7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19-2.51).ConclusionsBiologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.

Published
2021

41. Chronic Inflammatory Disease, Lifestyle and Treatment Response (BELIEVE)

Author

Hospital of Southern Jutland, University Hospital Bispebjerg and Frederiksberg, University of Copenhagen, Odense University Hospital, University of Aarhus, Aalborg University Hospital, Herning Hospital, Esbjerg Hospital - University Hospital of Southern Denmark, Sygehus Lillebaelt, Aalborg University, University of Kiel, Colitis-Crohn Foreningen, Herlev Hospital, Regionshospitalet Silkeborg, Aarhus University Hospital, The Danish Psoriasis Association, and Vibeke Andersen, Professor

Published
2021

43. Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn’s disease: a cross-sectional study

Author

M. M. van de Meeberg, M. L. Seinen, H. H. Fidder, M. Lin, B. Oldenburg, N. K. de Boer, G. Bouma, R. de Jonge, M. Bulatović Ćalasan, and the Dutch Initiative on Crohn and Colitis (ICC)

Subjects
Crohn’s disease, Methotrexate, Pharmacokinetics, Therapeutic drug monitoring, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Methotrexate is an immunomodulatory drug for patients with Crohn’s disease. Erythrocyte MTX-polyglutamates (MTX-PG1-5) may be used for therapeutic drug monitoring (TDM) as MTX-PG is thought to mediate MTX’s efficacy. Information on determinants of the concentration of MTX-PG in patients with Crohn’s disease is lacking. We aim to identify clinical and biochemical determinants of the erythrocyte MTX-PG1-5 and MTX-PGtotal concentration in patients with Crohn’s disease. Methods Adults with Crohn’s disease on methotrexate treatment who visited the outpatient clinic of Amsterdam UMC were included. Erythrocyte MTX-PGs were measured by tandem mass spectrometry. Results Nineteen patients were included, with a median duration of MTX use of 77 months (range 7–202). Twelve patients received MTX monotherapy, whereas 7 patients were on concomitant TNF-α inhibitors. The mean dose of MTX was 15.5 mg (SD ± 2.8) and 12 (63%) patients used subcutaneous MTX. MTX-PG1-5 were successfully measured in 18 patients, showing substantial variability in concentrations of MTX-PGtotal and individual species. The median MTX-PGtotal was 117.1 nmol/L (range 46.4–258.7) with preferential accumulation of MTX-PG3 (43.1 nmol/L, range 15.3–96.1). Patients on subcutaneous compared to oral MTX had higher median MTX-PG(4,5) levels (55 versus 9 nmol/L, p = 0.01). Higher age (β = 0.71) and lower estimated glomerular filtration rate (β = − 0.52) were associated with a significantly higher MTX-PGtotal concentration (R2 = 0.60, p = 0.001). Conclusion MTX-PG concentrations display a considerable inter-individual variability. Higher MTX-PG accumulation is associated with subcutaneous administration, higher age, and lower renal function in Crohn’s disease patients.

Published
2022
Full Text
View/download PDF

45. Modeling Patient Response to a Therapeutic Diet in Crohn's Disease (TDI)

Author

Crohn's and Colitis Foundation, University of Alberta, University of Guelph, University of British Columbia, Alphabiomics, University of Birmingham, and Maitreyi Raman, Clinical Associate Professor, Director Clinician Investigator Program (CIP), Medical Director Alberta's Collaboration of Excellence for Nutrition in Digestive Diseases (Ascend) , Medical Director Nutrition Services

Published
2020

47. Value of Fecal Calprotectin Measurement During the Initial Period of Therapeutic Anti-Tubercular Trial

Author

Hyeong Ho Jo, Eun Young Kim, Jin Tae Jung, Joong Goo Kwon, Eun Soo Kim, Hyun Seok Lee, Yoo Jin Lee, Kyeong Ok Kim, Byung Ik Jang, and the Crohn’s and Colitis Association in Daegu-Gyeongbuk

Subjects
diagnosis, fecal calprotectin, intestinal tuberculosis, therapeutic anti-tubercular trial, Internal medicine, RC31-1245, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background/Aims The diagnosis of intestinal tuberculosis (ITB) is often challenging. Therapeutic anti-tubercular trial (TATT) is sometimes used for the diagnosis of ITB. We aimed to evaluate the changing pattern of fecal calprotectin (FC) levels during TATT in patients with ITB. Methods A retrospective review was performed on the data of 39 patients who underwent TATT between September 2015 and November 2018 in five university hospitals in Daegu, South Korea. The analysis was performed for 33 patients with serial FC measurement reports. Results The mean age of the participants was 48.8 years. The final diagnosis of ITB was confirmed in 30 patients based on complete mucosal healing on follow-up colonoscopy performed after 2 months of TATT. Before starting TATT, the mean FC level of the ITB patients was 170.2 μg/g (range, 11.5-646.5). It dropped to 25.4 μg/g (range, 11.5-75.3) and then 23.3 μg/g (range, 11.5-172.2) after one and two months of TATT, respectively. The difference in mean FC before and one month after TATT was statistically significant (p

Published
2022
Full Text
View/download PDF

48. Diet Study on Ulcerative Colitis

Author

Broad Medical Research Program Crohn's and Colitis Foundation and Maria Abreu, Professor of Medicine

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results